# US 2021/0198696 A1 · Gene editing method using virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0198696 A1
- Document ID: US20210198696A1
- Status: Published application
- Kind: A1
- Application number: 16/475,128
- Filed: 2017-12-29
- Published: 2021-07-01
- Earliest claimed: 2016-12-29
- Assignees: Applied Stemcell, Inc.
- Applicants: Applied Stemcell, Inc.
- Inventors: Ling-jie KONG; Mi SHI; Hainan CHEN; Ruby Yanru TSAI
- Web page: https://patentgrep.com/patent/US20210198696A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/00: Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00)
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/8616: {Special methods for targeting systems}
- C12N 15/90: Stable introduction of foreign DNA into chromosome
- C12N 15/907: {in mammalian cells}
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- A01K 2267/0306: Animal model for genetic diseases
- C12N 2740/15011: Lentivirus, not HIV, e.g. FIV, SIV
- C12N 2750/14111: Dependovirus, e.g. adenoassociated viruses
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12Y 301/00: Hydrolases acting on ester bonds (3.1)
- C12Y 301/21: Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C12Y: ENZYMES

## Abstract

Provided is a method of inserting a polynucleotide sequence into a genome of a cell. The method comprises: generating a double-strand break at a target site of the genome; and introducing into the cell a virus. The virus comprises a nucleic acid comprising the polynucleotide sequence to be inserted or the complementary sequence thereof. The nucleic acid does not comprise a homologous arm or comprises very short (5˜25 bp) homologous arms corresponding to the target site. Also provided herein is a composition for inserting a polynucleotide sequence into a genome of a cell. The composition comprises a site-specific nuclease capable of generating a DNA double-strand break at a target site of the genome and a virus comprising a nucleic acid comprising the polynucleotide sequence or the complementary sequence thereof.

## Claims

### Claim 1

A method of inserting a polynucleotide sequence into a genome of a cell the method comprising:
generating a DNA double-strand break at a target location of the genome; and
introducing into said cell a virus, wherein said virus comprises a nucleic acid comprising the polynucleotide sequence or the complementary sequence thereof, wherein the nucleic acid does not comprise a homologous arm corresponding to the target site.

### Claim 2 (depends on 1)

The method of claim 1, wherein the nucleic acid comprises a microhomologous arm.

### Claim 3 (depends on 1)

The method of claim 1, wherein the virus is a double strand DNA (dsDNA) virus or a virus with dsDNA intermediate during virus life cycle.

### Claim 4 (depends on 1)

The method of claim 1, wherein the virus is an adeno-associated virus, a retrovirus or a lentivirus.

### Claim 5 (depends on 1)

The method of claim 1, wherein the nucleic acid is single-strand DNA (ssDNA) or double-strand DNA (dsDNA).

### Claim 6 (depends on 1)

The method of claim 1, wherein the polynucleotide sequence encodes B domain deleted Factor VIII.

### Claim 7 (depends on 1)

The method of claim 1, wherein the double-strand break is generated via introducing into the cell a composition comprising a site-specific nuclease.

### Claim 8 (depends on 7)

The method of claim 7, wherein the site-specific nuclease is a CRISPR-associated (Cas) nuclease.

### Claim 9 (depends on 8)

The method of claim 8, wherein the composition further comprises a CRISPR-Cas guide RNA directed to the target site.

### Claim 10 (depends on 7)

The method of claim 7, wherein the site-specific nuclease is a transcription activator-like effector nuclease or a zinc finger nuclease.

### Claim 11 (depends on 1)

The method of claim 1, wherein the target site is within a coding region, a safe-harbor locus or a non-coding region.

### Claim 12 (depends on 1)

The method of claim 1, wherein the cell is a human cell.

### Claim 13

A composition for inserting a polynucleotide sequence into a genome of a cell, said composition comprising:
a site-specific nuclease capable of generating a double-strand break at a target site of the genome; and
a virus comprising a nucleic acid comprising the polynucleotide sequence or the complementary sequence thereof, wherein the nucleic acid does not comprise a homologous arm corresponding to the target site.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the nucleic acid comprises a microhomologous, arm.

### Claim 15 (depends on 13)

The composition of claim 13, wherein the virus is a double strand DNA (dsDNA) virus or a virus with dsDNA intermediate during virus life cycle.

### Claim 16 (depends on 13)

The composition of claim 13, wherein the virus is an adeno-associated virus, a retrovirus or a lentivirus.

### Claim 17 (depends on 13)

The composition of claim 13, wherein the nucleic acid is single-strand DNA (ssDNA) or double-strand DNA (dsDNA).

### Claim 18 (depends on 13)

The composition of claim 13, wherein the polynucleotide sequence encodes B domain deleted Factor VIII.

### Claim 19 (depends on 13)

The composition of claim 13, wherein the site-specific nuclease is a CRISPR-associated (Cas) nuclease and the composition further comprises a CRISPR-Cas guide RNA directed to the target site.

### Claim 20 (depends on 13)

The composition of claim 13, wherein the site-specific nuclease is a transcription activator-like effector nuclease or a zinc finger nuclease.
